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ABSTRACT 
Background and Objectives：Plasma adiponectin, which decreases the progression of atherosclerosis and insulin 
resistance, as well as suppressing lipid accumulation in macrophages, is decreased in patients with acute myocardial 
infarction and unstable angina pectoris; however, the correlation between plasma adiponectin and vasospastic angina 
pectoris (VAP) remains to be verified. We compared the plasma adiponectin concentration between patients with 
VAP and other coronary artery diseases; moreover, we investigated the association between the plasma adiponectin 
concentration and VAP. Subjects and Methods：Following coronary angiography for the evaluation of chest pain, 
395 subjects (180 women and 215 men) were divided into 4 groups: acute coronary syndrome (ACS)(n=117), VAP 
(n=94), stable angina pectoris (SAP)(n=108) and angiographically normal coronary artery (n=76). The acetyl-
choline provocation test was used to confirm VAP, and plasma adiponectin concentrations were measured in all 
participants. Results：The plasma adiponectin concentrations in patients with VAP and ACS were significantly 
lower than that of the normal coronary artery group (6.6±5.4 vs. 5.2±4.0 vs. 9.0±6.2 μg/mL, p<0.001, respec-
tively). A multivariate analysis indicated that plasma adiponectin [odd ratio (OR) 0.744, 95% confidence interval 
(CI) 0.645 to 0.858, p=0.001], smoking (OR 2.054, 95% CI 1.027 to 4.106, p=0.042) and age (OR 0.966, 95% 
CI 0.935 to 0.997, p=0.031) were independently correlated in patients diagnosed with VAP. Conclusion：Our 
results suggest that a decreased plasma adiponectin concentration may be associated with VAP. (Korean Circulation 
J 2006;36:255-260) 
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Introduction 
 
The precise mechanisms of vasospastic angina pectoris 
(VAP) remain to be fully understood. Endothelial dys-
function, with a systemic alteration in nitric oxide pro-
duction, may be a cause of VAP.1)2) Even though the 
long-term survival of patients with VAP has been accep-
table, occasional cases of acute myocardial infarction and 
sudden cardiac death have been reported.1)3) Therefore, 
a prompt diagnosis for the proper treatment is impor-
tant for patients with VAP. 
Much work has been published regarding the role of 
adiponectin in the progression of atherosclerosis, the 
suppression of lipid accumulation in human monocyte-
derived macrophages and decreasing in insulin resis-
tance.4-7) Moreover, adiponectin inhibits macrophage to 
foam cell transformation.8) Plasma adiponectin is dec-
reased in patients with coronary artery diseases, espe-
cially in those with acute coronary syndrome(ACS)9) 
however, the correlation between plasma adiponectin and 
VAP, to our knowledge, remains to be fully investigated. 
In this single centered observational study, we compa-
red the plasma adiponectin concentrations between pa-
tients with VAP and other coronary artery diseases; mo-
reover, we investigated the association between plasma 
adiponectin and VAP. 
 
Subjects and Methods 
 
Study patients 
A total of 395 subjects(180 women and 215 men) 
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with suspected coronary artery disease, between Novem-
ber 2002 and March 2004, who underwent coronary 
angiography(CAG) for the evaluation of chest pain 
were included in this study. The study was approved by 
the institutional review board at our institution. The 
potential risks were explained, after which each parti-
cipant provided written informed consent before the 
procedures. Patients in the VAP group(n=94) with an 
episode of spontaneous angina at rest, associated with ST 
segment changes on 12-lead electrocardiogram (ECG) 
or ambulatory ECG underwent CAG with acetylcholine 
chloride(ACh) provocation. The VAP group included 
patients with an angiographically documented coronary 
spasm associated with ischemic ST segment changes after 
an intracoronary injection of ACh. The VAP group was 
compared with the following 3 groups: ACS(n=117), 
stable angina pectoris(SAP)(n=108) and angiographi-
cally normal coronary artery(n=76) without ischemic 
changes after an intracoronary injection of ACh. The 
ACS group(n=117) included patients with acute myo-
cardial infarction(n=33) and unstable angina pecto-
ris(n=84). 
Acute myocardial infarction was diagnosed on the ba-
sis of clinical symptoms, ECG evidence of a greater than 
0.1 mV ST elevation in at least 2 leads(in cases of ST 
elevation myocardial infarction), and a greater than two-
fold increase in the level of serum CK-MB from the 
upper limit of the normal range. CAG confirmed the 
occlusion of a coronary artery with a TIMI grade flow 
of less than 3 for acute myocardial infarction. Unstable 
angina pectoris was diagnosed on the basis of the clini-
cal symptoms(class IB, IIB, IIIB in the Braunwald clas-
sification),10) the CAG finding of greater than 70% ste-
nosis in at least one coronary artery, and no significant 
elevation in the level of serum CK-MB. Stable angina 
pectoris was diagnosed on the basis of typical chest pain 
during an exercise test and the CAG finding of greater 
than 70% stenosis in at least one coronary artery. The 
normal coronary group included patients with normal 
CAG findings and a negative ACh provocation test. Pa-
tients with malignancies, renal insufficiency and chronic 
inflammatory disease were excluded from entry into the 
study. 
Diabetes mellitus was defined as a history of diabe-
tes, a fasting plasma glucose concentration greater than 
or equal to 126 mg/dL, or the use of hypoglycemic me-
dications. Systemic hypertension was defined as a systolic 
blood pressure greater than or equal to 140 mmHg and/ 
or a diastolic pressure greater than or equal to 90 mmHg 
and/or the use of antihypertensive medication. Smokers 
were defined as those with a current or recent history 
of smoking within the past 1 year. Hyperlipidemia was 
defined as a total cholesterol level greater than or equal 
to 200 mg/dL, a LDL cholesterol level greater than or 
equal to 130 mg/dL, or treatment with a lipid-lowering 
agent. A family history of premature coronary artery 
disease was defined as coronary artery disease in a male 
first-degree relative less than 55 years of age and a fe-
male first-degree relatives less than 65 years of age. The 
body mass index(BMI) was calculated from the body 
weight in kilograms divided by the square of the height 
in meters. 
  
Provocation test for VAP 
With the exception of sublingual nitroglycerin me-
dications, all vasodilator drugs were discontinued 72 
hours prior to the CAG. No study patient had taken 
nitroglycerin within 12 hours of the study. After the 
baseline coronary angiogram in multiple projections in 
patients with an episode of spontaneous angina at rest, 
associated with ST segment changes on 12-lead ECG 
or ambulatory ECG, an electrode catheter was inserted 
into the right ventricular apex through the right femoral 
vein. A temporary pacemaker was connected to the elec-
trode catheter, at a pacing rate of 40 beats/min. Acetyl-
choline chloride(Ovisot, Daiichi Pharmaceutical, Tokyo, 
Japan), dissolved in 0.9% saline, was injected into the 
left coronary artery over a 40 second period, at incre-
mental doses of 20, 50 and 100 μg. The interval between 
each injection was at least 5 minutes, and left coronary 
angiography was performed in cases of chest pain de-
velopment, ST segment changes or 1 minute after the 
termination of each injection. If no changes were de-
tected at the left coronary artery, incremental doses of 
20 and 50 μg of ACh were similarly injected into the 
right coronary artery. In cases of coronary artery spasm, 
200 to 400 μg nitroglycerin(Millisrol, Kayaku Co., To-
kyo, Japan) was injected into the provoked coronary 
artery. VAP was confirmed when total or near total oc-
clusion occurred, with chest pain or ST segment changes 
on the ECG, or both. Calcium channel antagonists and/ 
or long acting nitrates were administered in patients with 
confirmed VAP. 
 
Laboratory analysis 
Blood samples were obtained from all patients on 
admission to the hospital by venipuncture into EDTA-
containing tubes, which were centrifuged to obtain 
plasma, with the plasma stored at -70℃. The plasma 
adiponectin concentration was assessed using a radio-
immunoassay(Linco Research, Inc. St. Charles, Missouri, 
USA). The sensitivity of this assay was 0.78 ng/mL. 
The coefficients for intra- and interassay variations were 
9.3 and 15.3%, respectively. Samples for all lipid profi-
les, including lipoprotein(a) [Lp(a)], were collected 
following overnight fasting. Total cholesterol, triglyceride 
and high-density lipoprotein(HDL) cholesterol were de-
termined by enzymatic methods, employing standard 
biochemical procedures, using a B.M. Hitachi automa-
ted clinical chemistry analyzer(Hitachi, Tokyo, Japan). 
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Moreover, low-density lipoprotein(LDL) cholesterol in 
patients without dysbetalipoproteinemia or those with 
triglyceride levels less than 400 mg/dL was calculated 
using the Friedewald’s formula. The Lp(a) concentration 
was measured by a particle enhanced immunoturbidi-
metric method using commercial kits(Roche Diagnostics, 
IN, USA). C-reactive protein(CRP) was measured using 
commercially available high-sensitive CRP assays(Dade 
Behring Inc., Newark, DE, USA). Fasting plasma glu-
cose was measured using the glucose oxidase method. 
 
Statistical analysis 
Data for the categorical variables are expressed as both 
the number and the percentage of patients. For conti-
nuous variables, data are expressed as the mean±SDs. 
A one way analysis of variance(ANOVA) was used to 
compare variables between the four different groups. Post 
hoc comparisons between different groups were made 
using the Tukey multiple comparison procedures and 
the chi-squared test for categorical variables. Pearson’s 
correlation coefficient analysis was used to assess for an 
association between the measured parameters. To iden-
tify the predictors of VAP, multivariate logistic regres-
sion analyses were used. Univariate variables, with p< 
0.20, were entered into the multivariate logistic models. 
Multivariate adjusted odds ratios are shown with a 95% 
confidence intervals(CI). Differences were considered 
significant at p<0.05. All statistical analyses were per-
formed using commercially available software(SPSS 11.0 
for windows, SPSS Inc., Chicago, Illinois). 
 
Results 
 
Baseline patient characteristics 
The clinical characteristics of patients for the diffe-
rent groups are shown in Table 1. Patients with VAP were 
younger compared to those with SAP and ACS(56.6±
10.5 vs. 61.3±10.3 years, p=0.008 and 56.6±10.5 vs. 
Table 1. Baseline patient characteristics 
 ACS (n=117) VAP (n=94) SAP (n=108) NC (n=76) p 
Age (yrs) 61.4±10.3 56.6±10.5 61.3±10.3 57.1±11.0 <0.001* 
Post hoc† a‡ b a‡ b  
Men 75 (64.1%) 49 (52.1%) 54 (50.0%) 37 (48.7%) <0.023§
Diabetes mellitus 32 (27.4%) 14 (14.9%) 29 (26.9%) 06 (08.7%) <0.040§
Hypertension 63 (59.4%) 55 (67.9%) 57 (62.6%) 36 (52.2%) <0.385§
Cigarette smoking 54 (46.2%) 58 (61.7%) 39 (42.9%) 23 (33.3%) <0.042§
Hypercholesterolemia 35 (30.0%) 12 (12.8%) 17 (15.7%) 09 (11.8%) <0.002§
Family history of coronary artery disease 14 (12.8%) 08 (09.9%) 09 (09.9%) 06 (08.8%) <0.390§
Body mass index (kg/m2) 24.3±2.60 24.0±2.40 24.2±2.30 23.7±2.60 <0.464* 
*: statistical significances were tested by a one way analysis of variances between the groups, †: the same letters indicate no significant difference
between groups, based on the Tukey’s multiple comparison test, ‡: difference in p<0.05 compared with the normal coronary artery group, §: two
by four chi-squared test with linear by linear association. ACS: acute coronary syndrome, VAP: vasospastic angina pectoris, SAP: stable angina
pectoris, NC: normal coronary 
 
Table 2. Comparison of metabolic parameters between acute coronary syndrome, vasospastic angina, stable angina and normal coronary patients 
 ACS (n=117) VAP (n=94) SAP (n=108) NC (n=76) p* 
Adiponectin (μg/mL) 005 .2±4.00 006 .6±5.40 008 .3±5.90 009.0±6.20 <0.001
Post hoc†  a§   a,b‡  b,c  c  
Fasting blood sugar (mg/dL) 135 .1±72.1 105.4±39.0 108.3±42.7 099.5±32.4 <0.001
Post hoc†  a§  b  b  b  
HbA1c (%) 006.8±1.10 005.3±1.20 005 .4±0.90 005.1±1.10 <0.001
Post hoc†  a§  b  b  b  
Total cholesterol (mg/dL) 179 .0±49.2 179.5±36.7 181.0±43.3 173.0±27.1 <0.657
HDL-cholesterol (mg/dL) 043.2±13.2 046.5±12.5 045.4±12.2 045.0±11.3 <0.356
Triglyceride (mg/dL) 144.0±87.4 130.8±88.3 130.1±80.2 117.9±49.5 <0.254
LDL-cholesterol (mg/dL) 108.7±46.0 106.1±30.0 109.2±37.2 106.1±26.0 <0.917 
Lipoprotein (a) (mg/dL) 029.0±28.9 028.7±48.5 030.7±28.3 025 .8±22.5 <0.882
Uric acid (mg/dL) 005 .1±1.40 005.1±1.40 004.7±1.40 005 .0±1.70 <0.167 
CRP (mg/L) 06.66±7.06 02.20±4.31 00.90±1.12 00.76±1.17 <0.001
Post hoc†  a§  b  b  b  
*: statistical significances were tested by a one way analysis of variances between the groups, †: the same letters indicate no significant difference bet-
ween groups, based on the Tukey’s multiple comparison test, ‡: difference in p<0.05 compared with the normal coronary artery group, §: difference
in p<0.01 compared with the normal coronary artery group, ACS: acute coronary syndrome, VAP: vasospastic angina pectoris, SAP: stable angina
pectoris, NC: normal coronary, HDL: high-density lipoprotein, LDL: low-density lipoprotein, CRP: C-reactive protein 
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61.4±10.3 years, p=0.005, respectively), with signifi-
cantly higher rates of current smoking(Table 1). The 
prevalence of diabetes and hyperlipidemia were highest 
in patients with ACS(Table 1). There were no signifi-
cant differences in the prevalence of hypertension, family 
history of coronary artery disease or the body mass index. 
 
Laboratory findings 
The plasma adiponectin concentration in VAP was 
only significantly different from that of the normal co-
ronary group after the Post hoc analysis(6.6±5.4 vs. 
9.0±6.2 μg/mL, p=0.021)(Table 2)(Fig. 1). Fasting 
blood sugar, HbA1c and CRP were significantly higher 
only in the ACS group(all three variables p<0.001 by 
ANOVA). As shown in Table 3, there was a positive 
correlation between the plasma adiponectin concentra-
tion and HDL cholesterol(r=0.243, p<0.001) and a 
negative correlation between the plasma adiponectin 
concentration and triglyceride(r=-0.224, p<0.001). Mo-
reover, CRP(r=-0.241, p<0.001) and fasting blood sugar 
(r=-0.188, p=0.006) showed significant negative cor-
relations with the plasma adiponectin concentration. 
 
Logistic regression analysis 
As shown in Table 4, the univariate logistic regression 
analysis indicated the rates of VAP were significantly 
correlated with age, the plasma adiponectin concentration 
and smoking. The variables in the univariate regression 
analysis with p<0.20 were entered into the multivariate 
logistic model. The plasma adiponectin concentration 
(odd ratios [OR] 0.744, 95% CI 0.645 to 0.858, p= 
0.001), smoking(OR 2.054, 95% CI 1.027 to 4.106, 
p=0.042) and age(OR 0.966, 95% CI 0.935 to 0.997, 
p=0.031) were independently correlated in patients 
diagnosed with VAP. 
 
Discussion 
 
Adiponectin is the most abundant gene product in 
adipose tissue,11) but accounts for approximately 0.01% 
of the total plasma protein, with concentrations ranging 
from 5 to 30 μg/mL.12) The plasma adiponectin con-
centration is decreased in patients with hypertension, 
visceral obesity, diabetes mellitus and coronary artery 
disease.4)12-14) These findings suggest that adiponectin is 
intimately involved in various metabolism, endothelial 
dysfunction and atherogenesis processes. The precise 
mechanisms of how low plasma adiponectin concentra-
tions contribute to the development of VAP remain to 
be elucidated. Endothelial dysfunction may initiate and 
contribute to the development of VAP,15-17) with vascu-
lar smooth muscle hypersensitivity also considered to play 
a role in the process of VAP.15)18) Increased sympathetic 
activity and decreased vagal control, in addition to the 
vasoactive mediators, may also facilitate the progression 
of VAP.19) The anti-atherogenic properties of adiponec-
tin may delay the progression of endothelial dysfunc-
tion.4)5) Adiponectin has a potent inhibitory effect on 
the expression of adhesion molecules in endothelial cells 
and macrophages that protect against cardiovascular di-
sease.8)20) By reducing the expression of adhesion mole-
cules in the endothelium, adiponectin prevents the 
endothelium from early atherosclerotic vascular change. 
Adiponectin reduced the atherogenic transformation of 
macrophages to foam cells by suppressing the expression 
of scavenger receptors and by decreasing the cytokine 
production of macrophages.8) Adiponectin also inter-
feres with the tumor necrosis factor-α induced expres-
Table 3. Correlation of the plasma adiponectin concentration with
various other parameters 
 
Pearson correlation  
coefficient 
p 
Age (yrs) -0.069 <0.169 
Total cholesterol (mg/dL) -0.008 <0.879 
HDL-cholesterol (mg/dL) -0.243 <0.001 
Triglyceride (mg/dL) -0.224 <0.001 
LDL-cholesterol (mg/dL) -0.016 <0.770 
Lipoprotein (a) (mg/dL) -0.026 <0.664 
Uric acid (mg/dL) -0.208 <0.001 
CRP (mg/L) -0.241 <0.001 
Fasting blood sugar (mg/dL) -0.188 <0.006 
HbA1c (%) -0.181 <0.011 
Body mass index (kg/m2) -0.070 <0.194 
HDL: high-density lipoprotein, LDL: low-density lipoprotein, CRP:
C-reactive protein 
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Fig. 1. The plasma adiponectin concentration is significantly lower in
patients with vasospastic angina pectoris and acute coronary syndrome
compared with normal coronary patients (p=0.021 and p<0.001, res-
pectively). ACS: acute coronary syndrome, VAP: vasospastic angina
pectoris. 
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sion of endothelial adhesion molecules in endothelial 
cells.4) Therefore, hypoadiponectinemia may be associa-
ted with endothelial dysfunction, leading to VAP and 
other coronary artery diseases. Adiponectin might protect 
directly or indirectly against endothelial damage and 
interferes with the progression of vascular atheroscle-
rosis, thereby reducing the rate of VAP. 
The patients with VAP in this study showed lower 
plasma adiponectin concentrations, comparable with the 
levels found with ACS(6.6±5.4 vs. 5.2±4.0 μg/mL, 
p=0.26). A multivariate logistic regression analysis sho-
wed the plasma adiponectin concentration, smoking and 
age to be independently correlated with the presence of 
VAP. Our study also showed the plasma adiponectin 
concentration to be independently correlated with the 
presence of ACS(OR 0.849, 95% CI 0.787 to 0.911, p< 
0.001), which was similar to a previous report.9) To our 
knowledge, this is the first report to illustrate an inde-
pendent correlation between the plasma adiponectin 
concentration and VAP, and to infer that plasma adi-
ponectin may be utilized in the presence of VAP, in 
addition to other risk factors, such as smoking, age, men-
tal stress and oral contraceptive use.21)22) 
The incidence of VAP is known to be higher in Asian 
than Western countries,23) and has probably been 
underestimated due to the widespread use of calcium 
antagonists in hypertensive patients. We evaluated the 
possibilities of VAP in all cases of spontaneous angina 
at rest, associated with ST segment changes on 12-lead 
ECG or ambulatory ECG, and attempted to disconti-
nue the use of oral nitrate and calcium antagonist at 
least 72 hours before the procedure where appropriate, 
with the exception of intermittent sublingual nitrogly-
cerine medications. In this study, an intracoronary in-
jection of ACh in patients with VAP induced either 
focal or diffuse coronary artery spasms, which suggested 
endothelial dysfunction with a hypercontractile response 
of the vascular smooth muscle. A relatively low plasma 
adiponectin concentration was noted in patients with 
VAP, which presumably contributed to the endothelial 
dysfunction in patients with VAP. Endothelial dysfunc-
tion may lead to the decreased production of nitric 
oxide in the pathogenesis of VAP, which may accele-
rate atherosclerotic coronary artery diseases.15) Although 
the physiological function of adiponectin in humans is 
not fully understood, our cross-sectional data undoub-
tedly showed a trend for an inverse correlation between 
the plasma adiponectin concentration and the incidence 
of VAP. A long-term clinical follow-up with a larger 
group of participants will be needed to establish the 
cutoff value for differentiating the VAP from normal 
coronary groups. 
 
Study limitations 
The patients in our normal coronary artery group 
were angiographically normal; positive vascular remo-
deling cases could also have been included in the normal 
coronary artery group since intravascular ultrasound 
(IVUS) was not used in all cases. Moreover, hypoadi-
ponectinemia, leading to VAP and ACS, will require fur-
ther molecular studies to determine the exact cause-
and-effect of this link. 
Table 4. Logistical regression analysis for vasospastic angina pectoris 
Univariate Multivariate 
Parameters 
p OR 95% CI p OR 95% CI 
Age (yrs) 0.004 0.969 0.948-0.990 0.031 0.966 0.935-0.997 
Women 0.608 1.129 0.710-1.796 - - - 
Adiponectin (μg/mL) 0.001 0.796 0.719-0.883 0.001 0.744 0.645-0.858 
Diabetes mellitus 0.104 0.593 0.316-1.113 0.078 2.814 0.892-8.880 
Hypertension 0.137 1.492 0.881-2.525 0.248 1.511 0.750-3.046 
Smoking 0.001 2.236 1.384-3.612 0.042 2.054 1.027-4.106 
Hyperlipidemia 0.105 0.576 0.295-1.123 0.919 0.942 0.298-2.978 
CRP (mg/L) 0.191 0.960 0.903-1.021 0.301 0.961 0.891-1.036 
FBS (mg/dL) 0.086 0.995 0.989-1.001 0.063 0.991 0.982-1.000 
Total cholesterol (mg/dL) 0.801 0.998 0.992-1.003 - - - 
HDL cholesterol (mg/dL) 0.189 1.013 0.994-1.033 0.164 1.022 0.991-1.053 
Triglyceride (mg/dL) 0.881 1.000 0.997-1.003 - - - 
LDL cholesterol (mg/dL) 0.637 0.998 0.992-1.005 - - - 
Lipoprotein (a) (mg/dL) 0.975 1.000 0.992-1.008 - - - 
Uric acid (mg/mL) 0.337 1.086 0.917 -1.286 - - - 
Body mass index (kg/m2) 0.819 0.988 0.893-1.094 - - - 
CI: confidence interval, CRP: C-reactive protein, FBS: fasting blood sugar, HDL: high-density lipoprotein, LDL: low-density lipoprotein, OR: odds
ratio 
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Conclusion 
Our results suggest that a decreased plasma adiponec-
tin concentration may be associated with VAP.  
This work was supported by the operating grant, SanHak-2004-12, 
from the Korean Society of Circulation. 
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